Biocryst Pharmaceuticals (BCRX) Total Current Liabilities (2010 - 2026)

Biocryst Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $195.4 million for Q1 2026.

• Quarterly Total Current Liabilities rose 39.71% year-over-year to $195.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $195.4 million (up 39.71% YoY) and the FY2025 annual result came in at $196.1 million, up 22.25% from the prior year.
• Total Current Liabilities was $195.4 million for Q1 2026 at Biocryst Pharmaceuticals, roughly flat from $196.1 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $196.1 million in Q4 2025 and bottomed at $81.0 million in Q1 2022.
• A 5-year average of $132.0 million and a median of $129.1 million in 2024 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 38.9% — and 2024, when it jumped 69.2%.
• Biocryst Pharmaceuticals' Total Current Liabilities stood at $105.5 million in 2022, then surged by 42.15% to $150.0 million in 2023, then gained by 6.93% to $160.4 million in 2024, then climbed by 22.25% to $196.1 million in 2025, then slipped by 0.34% to $195.4 million in 2026.
• Business Quant data shows BCRX's Total Current Liabilities at $195.4 million in Q1 2026, $196.1 million in Q4 2025, and $190.2 million in Q3 2025.